Post-cardiac injury syndrome

Article written and reviewed by Dr Luca Moretti

The post-cardiac injury syndrome, also referred to as post-cardiac injury syndrome or PCIS, comprises inflammatory pericardial and often pleural syndromes that develop after injury to the heart or adjacent structures. The initial event may be a myocardial infarction, surgery, an intracardiac procedure, or trauma. The characteristic clinical feature is an inflammatory response that may appear after a latency interval and persist beyond the initial mechanical injury.

The group includes Dressler syndrome, post-traumatic forms, and postpericardiotomy syndrome. Early pericarditis accompanying a transmural myocardial infarction is more directly related to epicardial extension of the injury and should be distinguished from the later immune-mediated form, although both lie within the broader spectrum of post-infarction pericardial disorders.

The main diagnostic challenge is to separate inflammation from bleeding, perforation, myocardial rupture, infection, and other complications of the initial setting. An effusion after a procedure is not sufficient to diagnose PCIS. Correct definition allows anti-inflammatory therapy when appropriate and, above all, prevents delay of necessary mechanical or surgical treatment.

Causes, clinical forms, and epidemiology

The ischemic injury may cause early pericarditis, generally in the first days after a large myocardial infarction, through involvement of the epicardial surface. Dressler syndrome occurs later, classically after weeks, and involves an inflammatory response not explained solely by immediate local irritation. The temporal distinction is useful but not absolute: presentation, biomarker dynamics, and concomitant complications must be interpreted together, especially when the true date of infarction is uncertain.

The timely reperfusion has reduced the extent of many infarctions and the frequency of classic pericardial manifestations. Historical percentages for Dressler syndrome therefore cannot be transferred directly to contemporary interventional cardiology. Its rarity does not justify ignoring it when pleuritic pain, fever, and effusions recur after an interval of improvement. In the same setting, new ischemia or a mechanical complication remain priority diagnoses to exclude.

The intracardiac procedures may trigger inflammation after ablation, lead implantation, coronary interventions, and other manipulations. The recognized extent of trauma does not always predict the subsequent response: even relatively limited injury may be followed by serositis. However, pain and a collection immediately after a procedure first require investigation for perforation or bleeding. A delayed inflammatory response and a mechanical complication may also coexist, making reassessment necessary if the course is not coherent.

The non-iatrogenic trauma, whether blunt or penetrating, may injure myocardium, pericardium, and pleura. Traumatic emergencies predominate in the initial phase; after stabilization, an inflammatory syndrome may emerge. Documentation of the trauma, blood in the sac, and repaired lesions helps reconstruct the relationship. A symptom-free interval does not exclude the association, but infection, organized collections, and unrecognized injuries should be considered before concluding that the process is immune-mediated.

The cardiac surgery is a common and relatively well-studied setting, but simple postoperative effusion is far broader than the clinical inflammatory syndrome. Opening of serosal surfaces, bleeding, and immune response may contribute to different degrees. Specific management of the postpericardiotomy form also includes operative factors, drains, and perioperative prevention. Evidence obtained in this setting should not be extended automatically to every ablation, device implantation, or myocardial infarction.

The epidemiologic heterogeneity depends on definitions, procedures, intensity of follow-up, and duration of observation. Studies that count any collection detected by echocardiography are not measuring the same phenomenon as those requiring pain, fever, and documented inflammation. To interpret frequency, the denominator and diagnostic criterion must be known. In an individual patient, reconstructing injury, latency, and phenotype is more useful than applying a general percentage to procedures with completely different anatomy and risk.

Immune pathogenesis and pathophysiology

The initial injury releases cellular components and danger signals that activate innate immunity. Exposure of cardiac antigens and injury to serosal surfaces may promote an adaptive response, while blood and its degradation products contribute to local irritation. Pathogenesis is supported by clinical and immunologic observations but is not defined by a single mechanism valid for every patient. The syndrome remains a heterogeneous clinical entity, not a positive immunologic test.

The inflammatory latency, tendency to recur, and response to anti-inflammatory therapy are consistent with an immune-mediated component. Autoantibodies against cardiac antigens have been described in specific studies without becoming routine diagnostic tests. Their presence may reflect antigen exposure rather than necessarily direct causation. Measurement of anti-myocardial antibodies is therefore not required for diagnosis, and a negative result does not exclude clinically plausible PCIS.

The pleuropericarditis explains the frequent association of pleuritic pain, friction rubs, and collections in both cavities. The pleural component may contribute substantially to dyspnea and pain even when the pericardial effusion is modest. The process should not be reduced to the amount of fluid surrounding the heart. A complete thoracic assessment helps distinguish pleural involvement, atelectasis, infection, and congestion, which may coexist after surgery or during recovery from myocardial infarction.

The pericardial exudation may remain limited or produce a significant pressure increase. After surgery or trauma, adhesions and clots alter fluid distribution and favor localized compression. The relationship between echocardiographic size and severity may be less intuitive than with a free circumferential collection. Anti-inflammatory treatment acts on exudate production but does not guarantee sufficiently rapid decompression once cardiac filling is already impaired.

The transient constriction may result from edema and inflammation of the pericardial layers, with temporary loss of distensibility. In other cases, fibrous organization leaves a persistent constraint. Distinction requires the clinical course, biomarkers, and imaging because thickening and enhancement alone do not indicate irreversibility. Simultaneous fluid and constraint may produce an effusive-constrictive picture in which drainage resolves only part of the obstacle to filling and systemic congestion.

The myocardial substrate affects tolerance of the syndrome. A recent infarction, pre-existing heart disease, or procedural injury may reduce reserve and amplify the effects of fever, tachycardia, and effusion. Elevated troponin after ablation or infarction does not automatically demonstrate new myocarditis; its dynamics and context must be assessed. Pathophysiology should therefore separate serosal inflammation from the underlying myocardial injury while recognizing that both may contribute to symptoms and functional limitation.

Clinical manifestations and diagnostic criteria

The chest pain is frequently pleuritic or positional and may be associated with fever, malaise, and dyspnea. Recurrence of symptoms after initial recovery suggests a process different from immediate procedural pain but is not specific. A pericardial or pleural friction rub supports suspicion when present; its absence does not exclude it. Pain severity is not proportional to the amount of effusion and alone cannot classify hemodynamic risk.

The temporal history should link the initial event, postoperative or post-infarction course, any asymptomatic interval, and new manifestations. Previous fever, infections, wound problems, anticoagulation, and treatment changes should be recorded. In device carriers, information about implantation and checks is needed; after ablation, the type and site of the procedure are useful. A detailed chronology helps distinguish a new episode from a persistent abnormality that never truly resolved.

The clinical criteria conventionally used require at least two of the following: fever without another cause, pericardial or pleuritic pain, pericardial or pleural friction rub, pericardial effusion, and pleural effusion associated with elevated C-reactive protein. Demonstration of inflammatory activity is essential to avoid confusing the syndrome with simple postoperative collections. These elements should be applied after a compatible injury and exclusion of alternatives; they are not an algorithm that replaces clinical reasoning.

The post-procedural fever requires interpretation according to timing and general condition. An early nonspecific response, device infection, pneumonia, or mediastinitis should not be reclassified as PCIS merely because a small effusion is present. Cultures and targeted investigations are indicated when the picture suggests infection. In particular, instability, chills, bacteremia, or local signs require active source investigation before immunosuppression is introduced.

The physical assessment includes perfusion, venous pressure, pulmonary findings, friction rubs, and signs of congestion. Persistent tachycardia, hypotension, oliguria, or syncope may indicate tamponade or other complications. After surgery, a loculated collection may compress the heart without the classic presentation, while sternal pain and respiratory abnormalities may hamper examination. Lack of concordance between symptoms and the first echocardiogram should not end the investigation if suspicion of compromise remains high.

The inflammatory burden is assessed through symptoms, temperature, C-reactive protein, and trends over time. A high value immediately after injury is not specific for PCIS; persistence or a new rise gains significance in context. A favorable response to anti-inflammatory therapy supports the interpretation but does not completely exclude other causes. The final diagnosis should describe the trigger, presence of pleuropericarditis, hemodynamic consequences, and the elements that allowed the most dangerous complications to be excluded.

Investigations and differential diagnosis of complications

The ECG looks for changes compatible with pericarditis, ischemia, arrhythmias, and conduction disturbances. After infarction, pacing, or ablation, the tracing may already be altered, making comparison with previous examinations essential. New ST-segment elevation should not be labeled pericarditic solely because pleuritic pain is present. If the picture suggests acute ischemia, the relevant diagnostic and therapeutic pathway retains priority while the diagnosis of PCIS is assessed subsequently.

The echocardiography evaluates collections, compression, ventricular function, and possible mechanical complications. After myocardial infarction, a new or enlarging effusion requires particular attention to free-wall rupture or a contained form. After procedures, perforation and bleeding must be considered. An unstable presentation requires urgent multidisciplinary assessment; it is inappropriate to wait for the effect of aspirin or colchicine to determine whether the collection is purely inflammatory.

The localized collections may require transesophageal echocardiography or CT when the transthoracic examination is insufficiently informative. Selection depends on stability, anatomy, and availability, while avoiding delay of management of an obvious emergency by sophisticated testing. CT can show hematomas, mediastinal abnormalities, lead position, and pulmonary disease. Suspicion of embolism or aortic injury requires appropriate protocols, not a generic chest scan without a defined clinical question.

The cardiac magnetic resonance may document pericardial inflammation and characterize the myocardium in stable uncertain, persistent, or recurrent cases. It is particularly useful when pain and biomarkers do not clarify whether residual activity exists or when constrictive physiology appears. Enhancement should not be interpreted in isolation as a need for indefinite treatment. Device compatibility and image quality must be assessed according to appropriate procedures rather than considering every implant an absolute contraindication.

The laboratory tests include complete blood count, inflammatory markers, renal function, and troponin according to context. Troponin dynamics after a recent event should be compared with the expected course and with ECG and imaging. Blood cultures, microbiologic analysis, or testing for thromboembolism are guided by suspicion. Measurement of cardiac autoantibodies has no routine role, and an extensive autoimmune panel is not justified solely by the presence of a syndrome temporally linked to injury.

The differential diagnosis also includes heart failure, volume overload, noninflammatory effusions, pneumonia, musculoskeletal pain, and drug reactions. If fluid is drained, hematologic analysis, cytology, and microbiology are chosen according to the question; hemorrhagic fluid may reflect trauma or anticoagulation and does not prove PCIS. Persistent fever or lack of response to therapy requires reconsideration of these alternatives rather than interpreting every difficult course as simple resistance to anti-inflammatory treatment.

Definition of the course and choice of level of care

The classification of the course distinguishes a first episode from incessant activity and recurrences after remission. This distinction must be based on a true interval of improvement and documentation of inflammation. Persistent pain after sternotomy or trauma, without compatible findings, is not automatically incessant pericarditis. Likewise, a stable residual collection may represent an anatomic sequela rather than active disease and should not by itself drive treatment escalation.

The hospital admission is indicated when there is instability, suspected tamponade, a mechanical complication, significant infection, relevant myocardial injury, or need for urgent testing. High fever, large effusion, subacute course, and lack of response increase the need for surveillance and investigation. The postoperative or post-procedural setting modifies risk even in the presence of apparently typical symptoms. Outpatient management is appropriate only after emergencies have been excluded and timely reassessment is realistically available.

The assessment for constriction is required if elevated venous pressure, ascites, edema, or exercise intolerance persist after fluid reduction. Doppler, tissue imaging, and the course help distinguish a transient inflammatory constraint from established fibrosis. Residual congestion may, however, also result from pre-existing ventricular or valvular dysfunction. Before attributing it to the pericardium, compatible physiology should be demonstrated, with invasive hemodynamics used when noninvasive information remains discordant.

The antithrombotic therapy should be reassessed in relation to indication, type of procedure, any bleeding, and planned anti-inflammatory treatment. The thrombotic risk of interruption may be high after coronary interventions or with some prosthetic valves. Automatic discontinuation of anticoagulants or antiplatelet drugs in every pericarditis is therefore incorrect. If hemopericardium is suspected or a procedure is necessary, the balance is defined with the treating team and appropriate reversal or correction measures.

The medication compatibility includes renal and hepatic function, gastrointestinal risk, and colchicine interactions. A patient after infarction or surgery often takes multiple drugs and may have rapid changes in organ function. A safe initial plan may become inappropriate during dehydration, infection, or introduction of an interacting antibiotic. Monitoring should not be limited to pain relief but should include tolerability, adherence, and ability to take the intended doses correctly.

The remission goals include disappearance of inflammatory symptoms, functional recovery, normalization of markers when previously elevated, and stability or regression of significant abnormalities. Immediate complete disappearance of every minimal echocardiographic finding is not always necessary. Reassessment should be scheduled with criteria for earlier review in the event of dyspnea, persistent fever, syncope, or general deterioration. In this way treatment tapering is based on a coherent set of data rather than a rigid deadline.

Treatment and limits of preventive strategies

The aspirin is generally preferred when pericarditis follows myocardial infarction or an antiplatelet indication coexists, with an anti-inflammatory dose and subsequent taper guided by response and tolerability. Standard antiplatelet doses are not equivalent to those needed to control active pericarditis. Selection must consider bleeding, gastroprotection, and other therapies. Other NSAIDs are not interchangeable without assessment in recent myocardial infarction and may interfere with cardiovascular safety or antiplatelet action.

The colchicine is added to anti-inflammatory treatment when appropriate to promote control and reduce recurrences. In adults, commonly used regimens are 0.5 mg once daily below 70 kg and twice daily at 70 kg or above, without a loading dose, with adjustments for organ function and interactions. Duration is generally at least three months in a first episode and longer in recurrences; the individual decision considers response, tolerability, and syndrome characteristics.

The corticosteroids are reserved for contraindications, intolerance, or inadequate response to initial approaches and for specific indications, after appropriate exclusion of infection. When used, low or moderate doses are generally preferred with slow taper after remission. In recent myocardial infarction, the choice requires additional caution regarding tissue healing and complications. It is inappropriate to use them to mask unexplained postoperative fever or automatically treat a collection without inflammation.

The refractory recurrences require confirmation of pericardial activity, verification of adherence, and reassessment of cause. Interleukin-1 blockade may be considered in selected recurrent inflammatory phenotypes according to recommendations and specialist expertise. Trials in recurrent pericarditis do not make all post-injury causes equivalent and do not replace exclusion of persistent perforation or infection. Even with a rapid response, maintenance and withdrawal should be planned, avoiding premature discontinuation driven solely by pain relief.

The invasive treatment is necessary for tamponade, collections not manageable conservatively, or specific diagnostic questions. A perforation, myocardial rupture, or active bleeding follows its own urgent pathway even if inflammation coexists. In persistent constriction, assessment distinguishes a reversible component from a lesion that may require pericardiectomy. Diuretic therapy may relieve congestion but should be calibrated to avoid compromising preload and must not replace treatment of the mechanical obstruction.

The prevention with colchicine has evidence mainly after cardiac surgery. COPPS and COPPS-2 studied reduction of postpericardiotomy syndrome with attention to gastrointestinal tolerability; they did not demonstrate that every postoperative effusion or every event after different procedures can be prevented in the same way. Prophylaxis after myocardial infarction, trauma, or lead implantation should not be extended indiscriminately on the basis of these results. Asymptomatic collections without inflammation require observation and causal evaluation rather than automatic anti-inflammatory prescription.

Prognosis, complications, and follow-up

A favorable course is common when the syndrome is recognized, mechanical complications are excluded, and treatment is maintained until stable remission. Overall prognosis, however, also depends on the initial event: a patient with a large infarction or advanced heart disease may remain limited after pericarditis resolves. Outcomes of the inflammatory response must therefore be separated from those of the underlying cardiac disease, avoiding interpretation of every residual symptom as pericardial activity.

The recurrences may appear during overly rapid tapering or after discontinuation, but not all reflect a treatment error. The immune response may persist and require a longer plan. Every new episode should be documented through coherent symptoms and findings; isolated chest pain may have other causes, especially after surgery or trauma. Accurate diagnosis avoids both undertreatment of a flare and prolonged drug exposure in the absence of inflammation.

The delayed tamponade is an important complication, especially when effusion, adhesions, and antithrombotic treatment interact. It may present after discharge with dyspnea, marked asthenia, tachycardia, or reduced perfusion without all classic signs. Patient instructions should make this change recognizable and indicate the need for urgent assessment. Availability of a scheduled follow-up does not justify waiting if symptoms worsen rapidly.

The persistent constriction is less common than simple inflammatory relapse but should be sought when congestion and functional limitation do not regress. Diagnosis requires compatible physiology and distinction from myocardial heart failure, valvular disease, and extracardiac causes of edema. A transient component may improve with therapy and time, whereas irreversible fibrosis requires a different assessment. Observation should be sufficiently careful to document reversibility without unnecessarily prolonging ineffective treatment in the face of deterioration.

The clinical follow-up integrates symptoms, physical examination, selected biomarkers, and echocardiography when informative. After procedures, monitoring of the device or anatomic repair may remain necessary regardless of remission. Resumption of exertion is graded after control of inflammation and takes into account any myocardial injury and the rehabilitation program. Return to activity should not be decided solely by disappearance of pain, especially if functional abnormalities, arrhythmias, or signs of hemodynamic compromise persist.

The continuity of care requires a clear summary of the trigger, investigations that excluded complications, and the drug-tapering plan. The cardiologist, proceduralist, and primary physician should be able to distinguish an expected residual finding from a new signal. The patient should know doses, expected duration, relevant interactions, and warning symptoms. Coordinated follow-up supports recovery and reduces the risk that a treatable syndrome becomes a sequence of episodically treated relapses without overall reassessment of the disease.

References
1. Schulz-Menger J et al. 2025 ESC Guidelines for the management of myocarditis and pericarditis. European Heart Journal. 2025;46(40):3952-4041.
2. Klein AL et al. Pericardial Diseases: International Position Statement on New Concepts and Advances in Multimodality Cardiac Imaging. JACC: Cardiovascular Imaging. 2024;17(8):937-988.
3. Adler Y et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC). Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2015;36(42):2921-2964.
4. Imazio M, Hoit BD. Post-cardiac injury syndromes. An emerging cause of pericardial diseases. International Journal of Cardiology. 2013;168(2):648-652.
5. Sasse T, Eriksson U. Post-cardiac injury syndrome: aetiology, diagnosis, and treatment. ESC e-Journal of Cardiology Practice. 2017;15:Online scientific resource. Accessed September 26, 2026. https://www.escardio.org/communities/councils/cardiology-practice/scientific-documents-and-publications/ejournal/volume-15/Post-cardiac-injury-syndrome-aetiology-diagnosis-and-treatment/.
6. Imazio M et al. COlchicine for the Prevention of the Post-pericardiotomy Syndrome (COPPS): a multicentre, randomized, double-blind, placebo-controlled trial. European Heart Journal. 2010;31(22):2749-2754.
7. Imazio M et al. Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: the COPPS-2 randomized clinical trial. JAMA. 2014;312(10):1016-1023.
8. Mauro AG et al. The Role of NLRP3 Inflammasome in Pericarditis: Potential for Therapeutic Approaches. JACC: Basic to Translational Science. 2021;6(2):137-150.
9. Spodick DH. Acute cardiac tamponade. New England Journal of Medicine. 2003;349(7):684-690.
10. Welch TD et al. Echocardiographic diagnosis of constrictive pericarditis: Mayo Clinic criteria. Circulation: Cardiovascular Imaging. 2014;7(3):526-534.
11. Sagristà-Sauleda J et al. Effusive-constrictive pericarditis. New England Journal of Medicine. 2004;350(5):469-475.
12. Imazio M et al. A randomized trial of colchicine for acute pericarditis. New England Journal of Medicine. 2013;369(16):1522-1528.
13. U.S. National Library of Medicine. COLCHICINE tablet, film coated: prescribing information. DailyMed. n.d. Accessed September 26, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50b9c910-49a3-4a57-80f5-dc36c09da4df.
14. Klein AL et al. Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis. New England Journal of Medicine. 2021;384(1):31-41.
15. Brucato A et al. Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial. JAMA. 2016;316(18):1906-1912.